Biomedical Research Entities Capabilities

Listed here are all the research entities under biomedical research. Click on the respective links to visit their web pages.

Bioinformatics Institute (BII)

BII was established in 2001 to train manpower and build capabilities in bioinformatics. BII focuses on theoretical approaches aimed at:

Understanding biomolecular mechanisms that underlie biological phenomena
Developing computational methods to support this discovery process
Experimental verification of predicted molecular and cellular functions of genes and proteins with biochemical methods

Research Capabilities

Biomolecular Function Discovery
Biomolecular Modelling and Design
Genome and Gene Expression Data Analysis
Imaging Infomatics
Translational Research (comprising of Natural Product Biology, Natural Product Chemistry and Antibody & Product Development Teams)

Visit BII

Bioprocessing Technology Institute (BTI)

BTI was established in 1990 with the mission to pursue innovative and cutting-edge research in bioprocess science and engineering leading to technologies which will impact biomedical science and bio-manufacturing as well as to nurture talent for the scientific community and industry. BTI specialises in:

Generating novel cell lines and biomolecules
Optimization of therapeutics production in prokaryotic and eukaryotic syste
Expansion and characterization of stem cells; product recovery, purification and analysis
Profiling of processes using “-omics” tools.

Research Capabilities

Immunology
Expression Engineering
Stem Cell Research
Animal Cell Technology
Microbial Cell
Downstream Processing
Analytics
"-OMICS" Technologies

Visit BTI

Institute of Bioengineering and Bioimaging (IBB)

The Institute of Bioengineering and Bioimaging (IBB) is located in Singapore's research and development hub for biomedical sciences, at the heart of Biopolis. The institute has office and laboratories located at Helios and Nanos Building and is staffed by 130 imaging experts, bioengineers, chemists, physicists, biologists and clinicians. IBB integrates the capabilities and technologies built up by the Institute of Bioengineering and Nanotechnology (IBN) and Singapore Bioimaging Consortium (SBIC), which were established in 2003 and 2004 respectively. The institute’s research activities are focused on biophotonics & bioimaging, bioengineering systems and biomedical devices & diagnostics.

Research Capabilities

Visit IBB

Institute of Medical Biology (IMB)

IMB was established in 2007 from the former Centre for Molecular Medicine. IMB’s Executive Director is Professor Birgit Lane. Its mission is to study mechanisms of human disease in order to discover new and effective therapeutic strategies for an improved quality of life. Our growing portfolio of strategic research topics aims to promote translational research on the mechanisms of human diseases with a cell-to-tissue emphasis that can help identify new therapeutic strategies for disease amelioration, cure, and eradication.

Research Capabilities

Stem Cells
Cancer
Genetic Diseases
Development and Differentiation

Visit IMB

Institute of Molecular and Cell Biology (IMCB)

The Institute of Molecular and Cell Biology (IMCB) was launched on 23 January 1985, with the official opening ceremony held on 2 October 1987 at the National University of Singapore (NUS). It subsequently became an autonomous research institute (RI) of A*STAR, moving to Biopolis in 2004. Today, IMCB has established itself as a world-class research institute in biomedical sciences with a focus on four major fields:

Animal Models of Development and Disease
Cancer Genetics and Therapeutics
Cell Biology in Health and Disease
Structural Biology and Drug Discovery

Research Capabilities

Advanced Molecular Pathology
Antibody Development
Cell Biology
Development Biology
Diagnostic and Therapeutic Development for Infectious Disease
Epigenetics
Genome-wide RNAi Screens
Humanized Model Organisms of Human Disease
Microfluidics Systems Biology
Quantitative Proteomics
Structural Biology
Translational Immunology

Visit IMCB

Singapore Institute for Clinical Sciences (SICS)

Founded in 2007, the Singapore Institute for Clinical Sciences (SICS) was the first institute within the Agency for Science, Technology and Research (A*STAR) to focus on clinical sciences and translational research. By leveraging on innovative approaches, technologies and seminal nationwide birth cohort studies, our esteemed researchers have made significant strides in pertinent healthcare fields such as metabolic diseases, pathways to normal growth and development, and nutritional sciences. The efficient and effective study of human health and diseases has allowed SICS to build gateways and an evidence base for positive health, allowing our scientific research to positively impact the social and economic fabric of our communities while also making a difference to health and human capacity in Singapore, Asia and globally.

Broad research areas:

Nutritional Sciences & Human Physiology
Metabolic Disease
Developmental pathways to Health and Disease

Visit SICS

Singapore Institute of Food and Biotechnology Innovation (SIFBI)

In April 2020, the Singapore Institute of Food and Biotechnology Innovation (SIFBI) was established with the aim of bringing cutting edge biotechnology in the forefront to drive innovation in food and many other applications. The institute pulls together research capabilities in areas such as food, nutrition, public health, biotechnology, manufacturing, agri-food technology, and safety research under one roof.

These capabilities will support the development of solutions for the needs of the Asian market, such as the discovery and production of health and sustainable foods. It also accelerates the transformation of the food industry, capturing new opportunities in established industries such as advanced manufacturing, specialty chemicals, biopharmaceuticals, and food manufacturing.

Research Capabilities

Discovery
Biotransformation
Fermentation
Safety
Nutrition
Shared Analytics Platform

Visit SIFBI

Singapore Immunology Network (SIgN)

The Singapore Immunology Network (SIgN) was initiated in December 2005 with the aim of expanding and strengthening immunology research capabilities in Singapore to support efficient translation into clinical applications in areas of medical needs. In January 2008, 6000m2 of new laboratory and office space was inaugurated as the home of SIgN, in the Immunos building at Biopolis. Human Immunology will be the focus of SIgN. Researchers at SIgN investigate immunity during infections and inflammatory conditions, including cancer, by using animal models to complement patient cohort studies, in an effort to translate bench discoveries into bedside medical treatments. Our Scientists' work is supported by cutting edge technological research platforms and core services. SIgN was also designed to attract and link up with companies in the biomedical field, feeding their pipelines with novel discoveries, in order to create a positive impact on Singapore’s economy. Since its establishment, SIgN has delivered outstanding scientific output that gained international recognition for Singapore’s Biomedical Sciences.

Research Capabilities

Infection
Inflammation
Immunoregulation

Visit SIgN

Skin Research Institute of Singapore (SRIS)

The Skin Research Institute of Singapore (SRIS), a collaboration between A*STAR, the National Healthcare Group, which comprises the National Skin Centre, and the Nanyang Technological University (NTU) was set up in 2013 to conduct research on skin and hair conditions prevalent in Asia and the tropics. SRIS is the largest skin research institute in the world, with over 200 researchers. It harnesses the expertise of scientists, clinicians and engineers in a unique, multi-disciplinary approach to skin and hair research to improve the well-being and health of consumers and patients alike.

The key research programmes at SRIS include:

Atopic Dermatitis
Acne & Sebaceous Gland
Asian Skin Microbiome
Wound Care
Skin Ageing and Pigmentation

Visit SRIS